Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children

JAMA

Volumn 279, Issue 10, 1998, Pages 756-761

  Palumbo, Paul E ^a,h   Raskino, Claire ^b   Fiscus, Susan ^c   Pahwa, Savita ^d   Fowler, Mary G ^e   Spector, Stephen A ^f   Englund, Janet A ^g   Baker, Carol J ^g  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEWBORN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RESPONSE TIME; RISK ASSESSMENT; SURVIVAL RATE; VIRUS LOAD;

EID: 0032507232     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.10.756     Document Type: Article

References (24)

1. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997;336:1343-1349.
2. Krogstad P, Kerr B, Anderson R, et al. Phase 1 study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 721.
3. Mueller BU, Zuckerman J, Nelson RP, et al. Update on the pediatric phase I/II study of the protease inhibitor ritonavir (ABT-538). In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract 722.
4. Melvin AJ, Mohan KM, Manns Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic, and immunologic responses of children with advanced HIV-1 disease treated with protease inhibitors. Pediatr Infect Dis J. 1997;16:968-974.
5. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146-154.
6. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
7. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med. 1996; 2:626-629.
8. Schlesinger M, Peters V, Jiang JD, Roboz JP, Bekesi JG. Increased expression of activation markers on CD8 lymphocytes in children with human immunodeficiency virus-1 infection. Pediatr Res. 1995;38:390-396.
9. + lymphocytes in healthy infants and early lymphocyte activation in uninfected infants of human immunodeficiency virus-infected mothers. Clin Diagn Lab Immunol. 1997;4:358-361.
10. Palumbo PE, Kwok S, Waters S, et al. Analysis of viral dynamics in HIV-infected infants with PCR-based assays. J Pediatr. 1995;126:592-595.
11. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. J Infect Dis. 1997;175: 1029-1038.
12. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med. 1997;336:1337-1342.
13. Englund JA, Báker CJ, Raskino C, et al. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children. Pediatr Infect Dis J. 1996;15:1025-1036.
14. Englund JA, Baker CJ, Raskino C, et al. A trial comparing zidovudine, didanosine, and combination therapy for initial treatment of symptomatic children infected with human immunodeficiency virus. N Engl J Med. 1997;336:1704-1712.
15. Kievits T, van Gemen B, van Strijp D, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods. 1991;35:273-286.
16. Altman DG. Practical Statistics for Medical Research. London, England: Chapman & Hall; 1991.
17. Kalbfleisch MD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
18. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997; 126:946-954.
19. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med. 1997;126:929-938.
20. Mellors J, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
21. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 1997;126:939-945.
22. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med. 1996;335: 1091-1098.
23. McKinney RE, PACTG Protocol 300 Team. Pediatric ACTG Trial 300: clinical efficacy of ZDV/3TC vs ddI vs ZDV/ddI in symptomatic, HIV-infected children. In: Programs and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America; September 16, 1997; San Francisco, Calif. Abstract 768.
24. Palumbo PE, Raskino C, Fiscus S, et al. Correlation of plasma HIV RNA levels with clinical outcome in a large pediatric trial (ACTG 152). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract LB14.